Home›Cardiology› DOAC plus calcium-channel blocker co-use raises major bleeding risk 21% in atrial fibrillation
DOAC plus calcium-channel blocker co-use raises major bleeding risk 21% in atrial fibrillationCombining certain heart medications may increase risk of major bleeding
HerzPublished August 9, 2026Study authors: Alves Kelly Francinny, Andrade de Faria Elisa, Rocha Dantas Clara, Ritter Lima Aminah Abrão Fauaz, D…PubMed ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider increased major bleeding risk when combining DOACs with non-dihydropyridine CCBs in AF.
This meta-analysis pooled data from 408,276 patients with atrial fibrillation and elevated thromboembolic risk, of whom 67,359 were using both a direct oral anticoagulant (DOAC) and a non-dihydropyridine calcium-channel blocker (CCB). The comparator was DOAC alone. The primary outcome was major bleeding, with any bleeding events as a secondary outcome.
The analysis found that co-use of DOACs and non-dihydropyridine CCBs was associated with a significantly higher incidence of major bleeding compared with DOAC alone (OR 1.21, 95% CI 1.18-1.43, p < 0.001). In contrast, the association with any bleeding events was not statistically significant (OR 1.21, 95% CI 0.83-1.77, p = 0.31).
The authors note that large randomized controlled trials are warranted to confirm these findings and to evaluate safety. The meta-analysis did not report follow-up duration, absolute event rates, or details on adverse events or discontinuations.
Clinically, this association suggests that when non-dihydropyridine CCBs are needed in patients with atrial fibrillation on DOACs, clinicians should weigh the increased risk of major bleeding and consider alternative rate-control strategies or closer monitoring. However, given the observational nature of the included studies, causality cannot be inferred, and the findings should be interpreted cautiously until randomized data are available.
How this fits prior evidence
This meta-analysis extends prior coverage on anticoagulation in atrial fibrillation by focusing on a specific drug-drug interaction. It confirms the importance of bleeding risk in AF management, aligning with prior findings that NOAC monotherapy reduces net adverse events in older AF patients with stents. It also contrasts with the safety of early DOAC initiation after stroke, suggesting that while DOACs are generally safe, co-administration with non-dihydropyridine CCBs may increase major bleeding risk. The finding addresses a gap in prior coverage by quantifying this interaction, though it does not directly compare with other rate-control options.
Researchers analyzed data from over 408,000 people to see how these combinations affect safety. They found that patients who took both medications experienced a significantly higher rate of major bleeding compared to those taking the blood thinner alone. While the risk for any minor bleeding event did not show a clear difference between the two groups, the jump in serious bleeding is a notable finding.
Because this information comes from a large data review rather than a controlled trial, more research is still needed to confirm these results exactly. If you are currently taking both of these medications for your heart health, it is important to talk with your doctor about how these findings might affect your specific treatment plan.
What this means for you:
Combining certain blood thinners and calcium channel blockers may increase the risk of major bleeding events.
Common questions
Does taking these two medications together increase my risk of bleeding?
Yes, the data shows that patients with atrial fibrillation who took both direct oral anticoagulants (DOACs) and non-dihydropyridine calcium channel blockers (CCBs) had a significantly higher incidence of major bleeding compared to those taking only the DOAC. This finding was based on an analysis of over 408,276 total patients.
Is there a difference in minor bleeding when using both drugs?
The study found no significant difference between the two groups when looking at any bleeding events. While major bleeding was more common in those taking both medications, the overall count of all bleeding incidents did not show a clear statistical difference.
Is this finding certain enough to change my treatment?
The data shows a significant link between the combination and major bleeding, but researchers note that large randomized controlled trials are still needed to confirm these findings and fully evaluate safety. You should discuss your specific medication plan with your doctor.
BACKGROUND: Oral anticoagulation is a cornerstone of stroke prevention in patients with atrial fibrillation (AF) and elevated thromboembolic risk. However, evidence regarding the association between co-use of direct oral anticoagulants (DOACs) and non-dihydropyridine calcium-channel blockers (CCBs) and bleeding risk remains controversial.
METHODS: We systematically searched PubMed, Embase, and the Cochrane Library for randomized clinical trials, cohort, and case-control studies evaluating bleeding risk associated with DOAC + CCB co-use in patients with AF. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for binary outcomes.
RESULTS: Nine studies met inclusion criteria, comprising 408,276 patients overall, of whom 67,359 were using DOACs + CCBs. Meta-analysis showed a significantly higher incidence of major bleeding with DOAC + CCB co-use compared with DOAC alone (OR 1.21 [95% CI 1.18-1.43]; p < 0.001; I = 21%). By contrast, there was no significant difference in any bleeding events between groups (OR 1.21 [95% CI 0.83-1.77]; p = 0.31; I = 77%).
CONCLUSION: Co-use of DOACs and non-dihydropyridine CCBs is associated with an increased risk of major bleeding, whereas the overall risk of any bleeding does not differ significantly. Large randomized controlled trials are warranted to confirm these findings and to further evaluate the safety of this combination.
